Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.

Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.

Abstract: Embodiments of a carrier and methods of its use are disclosed. In one method, a carrier is used with a container having a positioning device to be used with a medical diagnostic analyzer having a container loading device. This method comprises releasably mating a container retaining member disposed on the carrier with the positioning device on the container. The container retaining member on the carrier is substantially aligned with the container loading device on the medical diagnostic analyzer. The container is moved from the container retaining member on the carrier to the container loading device on the medical diagnostic analyzer.

Abstract: The present invention concerns the novel antiobiotic 6-O-methylerythromycin A form O solvate, a process for its preparation, pharmaceutical compositions comprising this compound and a method of use as a therapeutic agent.

Abstract: The present invention relates to a process for synthesizing oligosaccharides. The process involves contacting an acceptor moiety with unpurified sugar-nucleotides and/or unpurified glycosyltransferase to synthesize oligosaccharides.

Abstract: Embodiments of a carrier and methods of its use are disclosed. In one embodiment, the carrier is for a container having a positioning device to be used with a medical diagnostic analyzer. The carrier comprises a planar member and a container retaining member disposed on the planar member. The container retaining member has a configuration matable with a positioning device on the container such that the container is releasably retained with the carrier.

Abstract: A power transmission mechanism which is adapted to completely interrupt power transmission when a torque exceeds a predetermined value, and which has a simple configuration and is manufactured at low cost, and which is bidirectionally rotatable. When a torque, whose magnitude is not more than the predetermined value, is transmitted from a pulley (1) to a shaft (4), each of three elastic members is accommodated in such a manner as to extend over both of a holding portion (3) of the pulley and a holding part (6) of a hub (5). When an excessive torque, whose magnitude exceeds the predetermined value, is applied to the pulley, deformation of each of the elastic members is gradually enhanced by a compressive force applied from the pulley in a radial direction, so that each of the elastic members moves in the radial direction. Then, each of the elastic members further advances and is detached from a corresponding one of the holding portion of the pulley.

Abstract: The present invention relates to a process for the selective alkylation of intermediates of betaxolol.

Abstract: The present invention provides a plasmid containing a promoter sequence, a nucleotide sequence encoding an exogenous protein, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein. In a specific embodiment of the invention the encoded exogenous protein is human .beta.-casein and the encoded enzyme is a human kinase capable of phosphorylating recombinant .beta.-casein in a bacterial system. Phosphorylated recombinant human .beta.-casein synthesized using the plasmid of the invention is shown to have the same bioactivity as native human .beta.-casein.

Abstract: A solid phase synthesis method and intermediates useful in the process are disclosed for the preparation of diamino diol and diamino alcohol inhibitors of HIV protease.

Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.

Abstract: Embodiments of a fluid system and of methods of operation of a fluid system are disclosed. In one embodiment, the fluid system comprises at least one source of fluid, a nozzle and at least one first valve fluidly connecting the nozzle with the at least one source of fluid. The at least one first valve is movable between a first position where fluid flows between the at least one source of fluid and the nozzle, and a second position where fluid does not flow between the at least one source of fluid and the nozzle. A waste receptacle and at least one second valve fluidly connecting the waste receptacle with the at least one source of fluid are included. The at least one second valve is fluidly connected between the at least one source of fluid and the at least one first valve.

Abstract: A device for analyzing a whole blood sample is provided. The device comprises a conventionl hematology analyzer integrated with a fluorescence cyometry analyzer. A controller is provided for controlling the analyzers, obtaining and utilizing data from both and reporting a quantitative result. Methods are also provided for analyzing a whole blood sample. One such method comprises the steps of performing on a single instrument an analysis of impedance associated with the blood sample, an analysis of light scatter associated with the blood sample, and an analysis of fluorescence associated with the blood sample. Data is collected and utilized. A result is reported.

Abstract: A method and kit for measurement of a steroid by means of a competitive immunoassay, preferably a competitive enzyme immunoassay. The method and kit involve the use of a steroid analogue conjugated to a label. The steroids that are amenable to detection by the method and kit of the present invention include estradiol and progesterone. The method comprises the steps of:a. incubating a mixture of a test sample suspected of containing a given steroid, a solid phase coupled to an antibody specific for that steroid, and a conjugate of an analogue of that steroid to form steroid/antibody complexes and conjugate/antibody complexes on said solid phase;b. separating said solid phase from said mixture;c. measuring the amount of label present in said mixture or in said solid phase; andd. determining the amount of steroid in said sample from the amount of label. The kit comprises a solid phase coupled to an antibody specific for a steroid and a conjugate of an analogue of that steroid.

Abstract: A process of preparing a 6-O-alkyl derivative of 9-oxime erythromycin B is provided. Intermediates used in the preparation of a 6-O-alkyl 9-oxime erythromycin B are also provided. Pharmaceutical compositions containing a 6-O-alkyl derivative of 9-oxime erythromycin B and the use of those compositions to treat bacterial infections are also provided.

Abstract: The present invention discloses a process for the preparation of a compound having formula 4: ##STR1## The process comprises the step of reacting an enolate having the formula: ##STR2## with a Grignard reagent. The enolate salt is formed in situ from the reaction of a protected ester wherein M is an alkali metal. R.sub.6 and R.sub.7 are each hydrogen or are independently selected from ##STR3## wherein R.sub.a and R.sub.b are independently selected from hydrogen, lower alkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, lower alkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR4## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from lower alkyl, trifluoromethyl, alkoxy and halo. Alternatively, R.sub.6 is as defined above and R.sub.7 is R.sub.12 OC(O)-- wherein R.sub.12 is benzyl; or R.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded form ##STR5## wherein R.sub.

Abstract: Peptides having the formula:T-Gly-Val-D-Ile-Thr-Arg-Ile-U,V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-W,X-D-Arg-D-Ile-D-Arg-D-Thr-lle-D-Val-Y, andZ-Gly-Val-Ile-Thr-Arg-Ile-Uwherein T is absent or is selected from N-protecting group and a polypeptide of up to 12 amino acid residues optionally terminated with a N-protecting group; U is selected from Arg and Arg-NR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and alkyl of one to four carbon atoms; V is absent or a N-protecting group; W is selected from D-Arg and D-Arg-NR.sup.1 R.sup.2 ; X is absent or a N-protecting group; Y is selected from Gly and Gly-NR.sup.1 R.sup.2 ; and Z is 1-12 amino acid residues optionally terminated with a N-protecting group wherein at least one of the amino acid residues is a D-amino acid residue inhibit angiogenesis and are useful in the treatment of disease states such as cancer, arthritis, macular degeneration and diabetic retinopathyin which angiogenesis plays a role.

Abstract: A method for the preparation of D-chiro-inositol from kasugamycin, comprising the steps of: (a) reacting kasugamycin with an acetylating agent to form a crude hexa-acetate intermediate; (b) purifying the crude intermediate to form purified hexa-acetate intermediate; (c) deacetylating the purified intermediate to form D-chiro-inositol; and (d) isolating the D-chiro-inositol. The method permits efficient, large-scale preparation of D-chiro-inositol without the need for extensive chromatographic purification of the final D-chiro-inositol product.